Investors seeking short-term inverse exposure to specific areas of the U.S. equity market often turn to leveraged ETFs such as LABD and TZA. These funds do not compete directly; instead, they deliver alternative bearish strategies targeting different segments—one focused on the biotechnology industry and the other on the broader small-capitalization universe. In the current environment of shifting interest rate expectations and sector rotations, understanding their structural distinctions helps investors align positioning with particular market views or risk-management objectives.
The Direxion Daily S&P Biotech Bear 3X ETF seeks daily investment results, before fees and expenses, of 300% of the inverse (opposite) of the performance of the S&P Biotechnology Select Industry Index. This modified equal-weighted index measures the biotechnology sub-industry based on Global Industry Classification Standards (GICS). The fund maintains its -3x daily target through a portfolio of swap agreements and other derivatives that are rebalanced at the close of each trading day. It holds a small number of positions consisting primarily of cash equivalents and collateral alongside the derivative contracts. The net expense ratio is 1.07%. As a non-diversified, leveraged inverse product, LABD delivers concentrated exposure to biotechnology companies and carries elevated volatility relative to unleveraged sector funds.
The Direxion Daily Small Cap Bear 3X ETF seeks daily investment results, before fees and expenses, of 300% of the inverse of the performance of the Russell 2000 Index. This market-capitalization-weighted benchmark tracks approximately 2,000 small-capitalization companies drawn from the Russell 3000 Index. Like its counterpart, TZA achieves its -3x daily objective through swaps and derivatives subject to daily rebalancing. Portfolio holdings consist mainly of cash and collateral instruments supporting the derivative positions. The net expense ratio is 0.99%. The fund provides broad-based inverse exposure across small-cap sectors such as healthcare, financials, industrials, and information technology, resulting in a more diversified risk profile than single-sector leveraged products.
Both ETFs operate within the broader U.S. equity landscape where small-capitalization companies and biotechnology firms respond differently to macroeconomic drivers. Small-cap equities often exhibit greater sensitivity to domestic economic growth, interest rate changes, and credit conditions. Biotechnology companies face additional influences from clinical trial outcomes, regulatory approvals, research and development spending, and capital market access for funding. Recent market cycles have highlighted volatility in both areas stemming from shifts in monetary policy and investor risk appetite. Capital flows into or out of small caps and healthcare innovation themes can amplify price movements, creating environments where inverse leveraged products may serve tactical roles for short-term positioning.
In recent market cycles, both funds have demonstrated high volatility consistent with their -3x daily leverage and daily reset mechanisms. LABD tends to experience sharper moves tied to biotechnology-specific news flow and sector rotation within healthcare. TZA reflects broader small-cap dynamics, including earnings trends across multiple industries and overall economic sentiment. Relative positioning depends on whether investors anticipate weakness concentrated in biotechnology or across the small-cap universe. The daily rebalancing of both products means longer-term holding periods can produce returns that diverge significantly from the simple multiple of benchmark performance due to compounding and volatility drag.
Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. AI Screener
Based on observable structural factors, Tickeron’s AI would currently assign a modest probabilistic preference to TZA. Its slightly lower expense ratio, broader diversification across small-cap sectors, and longer operating history provide a marginally more balanced risk profile for tactical inverse exposure compared with the concentrated biotechnology focus of LABD. Investors should evaluate these characteristics against their specific market outlook and risk tolerance.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
LABD saw its Momentum Indicator move above the 0 level on November 12, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 90 similar instances where the indicator turned positive. In 85 of the 90 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.
The Moving Average Convergence Divergence (MACD) for LABD just turned positive on November 16, 2026. Looking at past instances where LABD's MACD turned positive, the stock continued to rise in 49 of 52 cases over the following month. The odds of a continued upward trend are 90%.
LABD moved above its 50-day moving average on November 13, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for LABD crossed bullishly above the 50-day moving average on November 20, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +10.42% 3-day Advance, the price is estimated to grow further. Considering data from situations where LABD advanced for three days, in 246 of 259 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
The Aroon Indicator entered an Uptrend today. In 141 of 156 cases where LABD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LABD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
LABD broke above its upper Bollinger Band on November 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
TZA saw its Momentum Indicator move above the 0 level on November 12, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 94 similar instances where the indicator turned positive. In 85 of the 94 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.
The Moving Average Convergence Divergence (MACD) for TZA just turned positive on November 17, 2026. Looking at past instances where TZA's MACD turned positive, the stock continued to rise in 42 of 44 cases over the following month. The odds of a continued upward trend are 90%.
TZA moved above its 50-day moving average on November 12, 2026 date and that indicates a change from a downward trend to an upward trend.
The 50-day moving average for TZA moved above the 200-day moving average on November 17, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +15.57% 3-day Advance, the price is estimated to grow further. Considering data from situations where TZA advanced for three days, in 251 of 275 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TZA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
TZA broke above its upper Bollinger Band on November 19, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for TZA entered a downward trend on November 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
| LABD | TZA | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 90% |
| Stochastic ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| Momentum ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| MACD ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| TrendWeek ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| TrendMonth ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| Advances ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| Declines ODDS (%) | 13 days ago 90% | 13 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| BUYZ | 33.82 | N/A | N/A |
| Franklin Disruptive Commerce ETF (BUYZ) | |||
| THMR | 23.19 | -0.45 | -1.90% |
| THOR AdaptiveRisk Dynamic ETF (THMR) | |||
| EFAX | 49.53 | -1.40 | -2.76% |
| State Street SPDR MSCI EAFE Fossil Fuel Reserves Free ETF (EFAX) | |||
| EJAN | 33.95 | -0.98 | -2.80% |
| Innovator Emerging Markets Power Buffer ETF January (EJAN) | |||
| SPUS | 51.62 | -2.49 | -4.60% |
| SP Funds S&P 500 Sharia Industry Exclusions ETF (SPUS) | |||